ArticleSchizophrenia (Heidelberg, Germany)2026
Clinical and neurobiological correlates of tardive dyskinesia in schizophrenia spectrum disorders and mood disorders.
Article in Schizophrenia (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Tardive dyskinesia (TD) is a persistent sensorimotor syndrome associated with antipsychotic exposure in schizophrenia spectrum disorders (SSD) and mood disorders (MOD), yet its neurobiological basis remains poorly understood. We investigated whether TD represents a distinct clinical and neurobiological phenotype across SSD and MOD. In this study, we examined a bicentric cohort of 453 individuals with SSD (n = 360) or MOD (n = 93), including early-psychosis (EP) and multiple-episode SSD patients. TD status was defined using Schooler and Kane criteria based on the Abnormal Involuntary Movement Scale (AIMS). Psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). Structural MRI data were processed using FreeSurfer (v7.4.1). Propensity score matching was applied to compare TD-positive and TD-negative patients while controlling for age, sex, illness duration, antipsychotic dose, and PANSS scores. TD prevalence was 10.6% in multiple-episode SSD (n = 31) and 7.5% in MOD (n = 7), whereas no EP patients met criteria for TD. Logistic regression identified male sex (p = 0.005) and higher PANSS general psychopathology scores (p = 0.021) as independent predictors of TD. TD-positive patients showed reduced paracentral cortical surface area in both the matched SSD sample (n = 86; p = 0.006, corr.) and the combined transdiagnostic sample (n = 179; p = 0.024, corr.). These alterations were absent in EP patients. In conclusion, our findings suggest that TD is a transdiagnostic phenomenon, occurring in both SSD and MOD. However, TD in SSD appears to be associated with a distinct clinical and neurobiological phenotype, marked by greater illness severity, male predominance, and focal sensorimotor cortical alterations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.